SCIENTIFIC ADVISORY BOARD
Nov. 8th 2012, gIcare pharma received today the non-objection letter (NOL) from Health Canada for Phase I program initiation with GIC-1001.
Oct. 25th, 2012, gIcare pharma just closed its first SAB meeting in Amsterdam. Clinical development strategies and UEGW highlights were both extensively discussed.
Mar. 1st, 2012, gIcare Pharma Inc announced the appointment of Dr. Mark Pruzanski, MD, CEO, Intercept Pharmaceuticals, as independent Director of the Board.
DDW, Orlando (USA), May 18-21, 2013
gIcare pharma will present the concept of GIC-1001 colonic analgesia and US colonoscopy market analysis.
BIO International Convention, Chicago (USA), Apr 20-24, 2013
gIcare pharma will present the most recent clinical Phase I data of GIC-1001.
Biotech Showcase, San Francisco (USA), Jan. 7-9, 2013
gIcare Pharma made a presentation on Jan 8 at Biotech Showcase 2012, San Francisco.
UEGW, Amsterdam (NL), Oct. 20-24, 2012
gIcare pharma attended the UEGW 2012 meeting in Amsterdam, the Netherlands. The Founders organized the first SAB meeting to discuss clinical development strategies and UEGW highlights.
Copyright © 2013 gIcare pharma Inc.